On June 18, 2025, the Food and Drug Administration sanctioned tafasitamab-cxix (Monjuvi, Incyte Corporation) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory folli...
IntroductionDiffuse midline glioma (DMG) remains one of the most aggressive and devastating brain tumors in children and young adults. Surgical removal is often impossible due to its deep-seated midli...
Diffuse midline glioma (DMG), specifically the H3K27-mutated subtype, is among the most malignant and lethal types of pediatric-type brain tumors. Marked by poor prognosis and ineffectiveness to tradi...
Gliomas IntroductionBrain gliomas, especially aggressive types such as glioblastoma multiforme (GBM), have long been extremely challenging to treat because of their insensitivity to traditional therap...
IntroductionHematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic system. Conventional trea...
CAR T Cell therapy in KoreaCAR T cell therapy is an advanced cancer treatment that has gained significant momentum in South Korea. It involves genetically modifying a patient’s T cells to recognize ...
August 2024: Vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), has been approved by the Food and Drug Admini...
August 2024: The Food and Drug Administration has given accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a genetically modified autologous T cell immunotherapy that target...
August 2024: The Food and Drug Administration has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for t...
In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people with locally advanced nasopharyngeal canc...